Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

CATX holding history

Perspective Therapeutics, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

CATX overviewAll 13F holders of CATXFull Q2 2026 holdings

Shares (Q2 2026)
444,917
Value
$1.52M
% of portfolio
<0.1%
Quarters held
22
Since Q1 2021
Holdings of CATX by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 2026444,917$1.52M<0.1%−75,988−14.6%ReducedHolders
Q1 2026520,905$2.17M<0.1%−405,426−43.8%ReducedHolders
Q4 2025926,331$2.55M<0.1%+285,188+44.5%AddedHolders
Q3 2025641,143$2.20M<0.1%+268,433+72.0%AddedHolders
Q2 2025372,710$1.28M<0.1%−96,808−20.6%ReducedHolders
Q1 2025469,518$1.00M<0.1%−102,230−17.9%ReducedHolders
Q4 2024571,748$1.82M<0.1%+485,362+561.9%AddedHolders
Q3 202486,386$1.15M<0.1%+68,084+372.0%AddedHolders
Q2 202418,302$182.5K<0.1%+9,745+113.9%AddedHolders
Q1 20248,557$10.2K<0.1%−9,653−53.0%ReducedHolders
Q4 202318,210$7.32K<0.1%+17,530+2,577.9%AddedHolders
Q3 2023680$186<0.1%−161−19.1%ReducedHolders
Q2 2023841$562<0.1%−4,161−83.2%ReducedHolders
Q1 20235,002$3.19K<0.1%−79,296−94.1%ReducedHolders
Q4 202284,298$21.1K<0.1%+83,618+12,296.8%AddedHolders
Q3 2022680$00.0%−16,778−96.1%ReducedHolders
Q2 202217,458$5.00K<0.1%+16,778+2,467.4%AddedHolders
Q1 2022680$00.0%−121,263−99.4%ReducedHolders
Q4 2021121,943$47.0K<0.1%+79,467+187.1%AddedHolders
Q3 202142,476$26.0K<0.1%+41,796+6,146.5%AddedHolders
Q2 2021680$1.00K<0.1%00.0%UnchangedHolders
Q1 2021680$1.00K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.